Mechanisms of endocrine resistance in breast cancer von Osborne, C Kent, Schiff, Rachel

Volltext

Towards personalized treatment for early stage HER2-positive breast cancer von Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

Volltext

Targeting HER2 for the Treatment of Breast Cancer von Rimawi, Mothaffar F, Schiff, Rachel, Osborne, C. Kent

Volltext

The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells von Wang, Hai, Yu, Cuijuan, Gao, Xia, Welte, Thomas, Muscarella, Aaron M., Tian, Lin, Zhao, Hong, Zhao, Zhen, Du, Shiyu, Tao, Jianning, Lee, Brendan, Westbrook, Thomas F., Wong, Stephen T.C., Jin, Xin, Rosen, Jeffrey M., Osborne, C. Kent, Zhang, Xiang H.-F.

Volltext

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer von Burstein, Matthew D, Tsimelzon, Anna, Poage, Graham M, Covington, Kyle R, Contreras, Alejandro, Fuqua, Suzanne A W, Savage, Michelle I, Osborne, C Kent, Hilsenbeck, Susan G, Chang, Jenny C, Mills, Gordon B, Lau, Ching C, Brown, Powel H

Volltext

Metastasis dormancy in estrogen receptor-positive breast cancer von Zhang, Xiang H-F, Giuliano, Mario, Trivedi, Meghana V, Schiff, Rachel, Osborne, C Kent

Volltext

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexp... von RIMAWI, Mothaffar F, MAYER, Ingrid A, SCHIFF, Rachel, KENT OSBORNE, C, CHANG, Jenny C, FORERO, Andres, NANDA, Rita, GOETZ, Matthew P, RODRIGUEZ, Angel A, PAVLICK, Anne C, TAO WANG, HILSENBECK, Susan G, GUTIERREZ, Carolina

Volltext

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance von Arpino, Grazia, Wiechmann, Lisa, Osborne, C. Kent, Schiff, Rachel

Volltext

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer von Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Kent Osborne, C., Schiff, Rachel

Volltext

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial von Johnston, Stephen, Puhalla, Shannon, Wheatley, Duncan, Ring, Alistair, Barry, Peter, Holcombe, Chris, Boileau, Jean Francois, Provencher, Louise, Robidoux, André, Rimawi, Mothaffar, McIntosh, Stuart A, Shalaby, Ibrahim, Stein, Robert C, Thirlwell, Michael, Dolling, David, Morden, James, Snowdon, Claire, Perry, Sophie, Cornman, Chester, Batten, Leona M, Jeffs, Lisa K, Dodson, Andrew, Martins, Vera, Modi, Arjun, Osborne, C Kent, Pogue-Geile, Katherine L, Cheang, Maggie Chon U, Wolmark, Norman, Julian, Thomas B, Fisher, Kate, MacKenzie, Mairead, Wilcox, Maggie, Huang Bartlett, Cynthia, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M, Jacobs, Samuel A

Volltext

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Lo... von DAVE, Bhuvanesh, MIGLIACCIO, Ilenia, RIMAWI, Mothaffar, SCHIFF, Rachel, ARTEAGA, Carlos, KENT OSBORNE, C, CHANG, Jenny C, GUTIERREZ, M. Carolina, WU, Meng-Fen, CHAMNESS, Gary C, WONG, Helen, NARASANNA, Archana, CHAKRABARTY, Anindita, HILSENBECK, Susan G, JIAN HUANG

Volltext

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer von Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

Volltext

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy von Li, Xiaoxian, Lewis, Michael T., Huang, Jian, Gutierrez, Carolina, Osborne, C. Kent, Wu, Meng-Fen, Hilsenbeck, Susan G., Pavlick, Anne, Zhang, Xiaomei, Chamness, Gary C., Wong, Helen, Rosen, Jeffrey, Chang, Jenny C.

Volltext

Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer von Mouabbi, Jason A., Osborne, C. Kent, Schiff, Rachel, Rimawi, Mothaffar F.

Volltext

An epigenomic approach to therapy for tamoxifen-resistant breast cancer von Feng, Qin, Zhang, Zheng, Shea, Martin J, Creighton, Chad J, Coarfa, Cristian, Hilsenbeck, Susan G, Lanz, Rainer, He, Bin, Wang, Lei, Fu, Xiaoyong, Nardone, Agostina, Song, Yongcheng, Bradner, James, Mitsiades, Nicholas, Mitsiades, Constantine S, Osborne, C Kent, Schiff, Rachel, O'Malley, Bert W

Volltext

The changing role of ER in endocrine resistance von Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel

Volltext

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer von Harvey, Jennet M, Clark, Gary M, Osborne, C Kent, Allred, D Craig

Volltext

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer von Rimawi, Mothaffar F, Niravath, Polly, Wang, Tao, Rexer, Brent N, Forero, Andres, Wolff, Antonio C, Nanda, Rita, Storniolo, Anna M, Krop, Ian, Goetz, Matthew P, Nangia, Julie R, Jiralerspong, Sao, Pavlick, Anne, Veeraraghavan, Jamunarani, De Angelis, Carmine, Gutierrez, Carolina, Schiff, Rachel, Hilsenbeck, Susan G, Osborne, C Kent

Volltext

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis von Kessler, Jessica D., Kahle, Kristopher T., Sun, Tingting, Meerbrey, Kristen L., Schlabach, Michael R., Schmitt, Earlene M., Skinner, Samuel O., Xu, Qikai, Li, Mamie Z., Hartman, Zachary C., Rao, Mitchell, Yu, Peng, Dominguez-Vidana, Rocio, Liang, Anthony C., Solimini, Nicole L., Bernardi, Ronald J., Yu, Bing, Hsu, Tiffany, Golding, Ido, Luo, Ji, Osborne, C. Kent, Creighton, Chad J., Hilsenbeck, Susan G., Schiff, Rachel, Shaw, Chad A., Elledge, Stephen J., Westbrook, Thomas F.

Volltext

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia von Niravath, Polly, Hilsenbeck, Susan G., Wang, Tao, Jiralerspong, Sao, Nangia, Julie, Pavlick, Anne, Ademuyiwa, Foluso, Frith, Ashley, Ma, Cynthia, Park, Haeseong, Rigden, Caron, Suresh, Rama, Ellis, Matthew, Kent Osborne, C., Rimawi, Mothaffar F.

Volltext